{"id":"abx-egf","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reaction"}]},"_chembl":{"chemblId":"CHEMBL2109616","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It is used to stimulate wound healing and tissue repair. ABX-EGF works by binding to the EGF receptor, which is involved in cell growth and differentiation.","oneSentence":"ABX-EGF is a recombinant human heparin-binding EGF-like growth factor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:20:26.441Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diabetic foot ulcers"}]},"trialDetails":[{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT06998940","phase":"PHASE3","title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-04-01","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8","enrollment":94},{"nctId":"NCT05638295","phase":"PHASE2","title":"Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-01","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":105},{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT03384238","phase":"PHASE1, PHASE2","title":"Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery","status":"RECRUITING","sponsor":"George Poultsides","startDate":"2018-02-07","conditions":"Pancreatic Adenocarcinoma","enrollment":27},{"nctId":"NCT06011772","phase":"EARLY_PHASE1","title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-12-18","conditions":"Colo-rectal Cancer","enrollment":2},{"nctId":"NCT03510208","phase":"PHASE1, PHASE2","title":"Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery","status":"RECRUITING","sponsor":"Stanford University","startDate":"2018-05-16","conditions":"Malignant Brain Neoplasm, Malignant Glioma","enrollment":46},{"nctId":"NCT04163952","phase":"PHASE1","title":"Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin","status":"TERMINATED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2020-01-31","conditions":"Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma","enrollment":5},{"nctId":"NCT03087071","phase":"PHASE2","title":"Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-12-29","conditions":"EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation","enrollment":59},{"nctId":"NCT03983993","phase":"PHASE2","title":"Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2019-10-15","conditions":"Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Microsatellite Stable","enrollment":26},{"nctId":"NCT02593175","phase":"PHASE2","title":"Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-11-03","conditions":"Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7","enrollment":43},{"nctId":"NCT02876107","phase":"PHASE2","title":"Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-10-06","conditions":"Breast Carcinoma, Breast Lump, Edema","enrollment":42},{"nctId":"NCT01814501","phase":"PHASE2","title":"Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab","status":"COMPLETED","sponsor":"John Hays","startDate":"2013-02-01","conditions":"Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":16},{"nctId":"NCT05177796","phase":"PHASE2","title":"Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-11","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8","enrollment":""},{"nctId":"NCT04117945","phase":"PHASE2","title":"Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2020-03-03","conditions":"BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma","enrollment":22},{"nctId":"NCT03992456","phase":"PHASE2","title":"Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2020-04-24","conditions":"Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma","enrollment":12},{"nctId":"NCT01307956","phase":"PHASE2","title":"Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2011-02-28","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma, Stage IIA Esophageal Cancer","enrollment":11},{"nctId":"NCT00113763","phase":"PHASE3","title":"Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-01-01","conditions":"Colorectal Cancer, Metastases","enrollment":463},{"nctId":"NCT00089635","phase":"PHASE2","title":"Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-08-01","conditions":"Colorectal Cancer, Metastases","enrollment":203},{"nctId":"NCT00054574","phase":"PHASE2","title":"Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2002-11","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT00867334","phase":"PHASE1, PHASE2","title":"New Individualized Therapy Trial for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Inova Health Care Services","startDate":"2009-06","conditions":"Colorectal Neoplasm, Colorectal Cancer","enrollment":10},{"nctId":"NCT03300609","phase":"PHASE3","title":"5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2018-02-27","conditions":"Colorectal Adenocarcinoma, RAS Wild Type, Stage III Colorectal Cancer AJCC v7","enrollment":4},{"nctId":"NCT00115765","phase":"PHASE3","title":"PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-06-01","conditions":"Colorectal Cancer","enrollment":1053},{"nctId":"NCT02508077","phase":"PHASE2","title":"FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2016-02-16","conditions":"Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer","enrollment":1},{"nctId":"NCT01009983","phase":"PHASE2","title":"Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2010-03","conditions":"Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer","enrollment":14},{"nctId":"NCT00798655","phase":"PHASE2","title":"Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Robert Ferris","startDate":"2007-11","conditions":"Cancer of Head, Cancer of Head and Neck, Cancer of Neck","enrollment":46},{"nctId":"NCT00836277","phase":"PHASE2","title":"Phase II Study of Irinotecan and Panitumumab","status":"COMPLETED","sponsor":"Weijing Sun, MD, FACP","startDate":"2009-05","conditions":"Esophageal Cancer","enrollment":24},{"nctId":"NCT00094835","phase":"PHASE1, PHASE2","title":"Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-01","conditions":"Lung Cancer, Non-Small Cell Lung Cancer","enrollment":51},{"nctId":"NCT01305772","phase":"PHASE2","title":"Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN","status":"TERMINATED","sponsor":"Neal Ready","startDate":"2011-01","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":6},{"nctId":"NCT00083616","phase":"PHASE2","title":"Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-03","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":185},{"nctId":"NCT00111761","phase":"PHASE2","title":"Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-07","conditions":"Colorectal Cancer","enrollment":43},{"nctId":"NCT01172717","phase":"PHASE2","title":"Study of Panitumumab in the Treatment of Carcinoid Syndrome","status":"WITHDRAWN","sponsor":"Boston Medical Center","startDate":"2013-07","conditions":"Carcinoid Syndrome","enrollment":""},{"nctId":"NCT00111774","phase":"PHASE2","title":"Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-03","conditions":"Colorectal Cancer, Carcinoma","enrollment":150},{"nctId":"NCT00425035","phase":"PHASE2","title":"Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2","status":"COMPLETED","sponsor":"Amgen","startDate":"2003-02","conditions":"Advanced Renal Cell Carcinoma","enrollment":115},{"nctId":"NCT00039273","phase":"PHASE2","title":"Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2002-07","conditions":"Colorectal Cancer","enrollment":44},{"nctId":"NCT00004879","phase":"PHASE1","title":"Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2000-04","conditions":"Colorectal Cancer, Esophageal Cancer, Kidney Cancer","enrollment":""},{"nctId":"NCT00113776","phase":"PHASE2","title":"Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT00101920","phase":"PHASE2","title":"ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Amgen","startDate":"2003-06","conditions":"Non-small Cell Lung Cancer, Neoplasm Metastasis, Lung Cancer","enrollment":50},{"nctId":"NCT00327119","phase":"PHASE2","title":"Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-04","conditions":"Metastatic Colorectal Cancer","enrollment":50},{"nctId":"NCT00091806","phase":"PHASE1","title":"Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-08","conditions":"Tumors, Oncology, Solid Tumors","enrollment":86},{"nctId":"NCT00425204","phase":"PHASE2","title":"Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-03","conditions":"Colorectal Cancer, Non-Small Cell Lung Cancer, Prostate Cancer","enrollment":31},{"nctId":"NCT00034346","phase":"PHASE2","title":"ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-01","conditions":"Non-Small Cell Lung Cancer, Neoplasm Metastasis, Lung Cancer","enrollment":194},{"nctId":"NCT00061126","phase":"PHASE2","title":"ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body","status":"COMPLETED","sponsor":"Abgenix","startDate":"2003-04","conditions":"Prostate Cancer","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ABX-EGF","genericName":"ABX-EGF","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABX-EGF is a recombinant human heparin-binding EGF-like growth factor. Used for Diabetic foot ulcers.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}